Tigecycline for Treatment of Rapidly Growing Mycobacteria

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-04-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

NCT00205816

Bacterial Infections

COMPLETED PHASE3

Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics

NCT01311349

Infection

COMPLETED

Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00079976

Gram-Positive Bacterial Infections Staphylococcus Infections Vancomycin Resistance +1 more

COMPLETED PHASE3

Tygacil Drug Use Investigation

NCT01789905

Intra-Abdominal Infections Skin Disease, Infectious

COMPLETED

Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment

NCT01072539

Complicated Skin and Skin Structure Infections Complicated Intra-abdominal Infections Community-Acquired Bacterial Pneumonia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the safety and efficacy of tigecycline in the treatment of drug resistant rapidly growing mycobacterial disease especially M. abscessus

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mycobacterium Abscessus Lung Disease Rapidly Growing Mycobacterial Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tigecycline

tigecycline titrated dose according to patient age and clinical status

Group Type EXPERIMENTAL

Tigecycline

Intervention Type DRUG

Tigecycline dosage based on age and clinical status of patient.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tigecycline

Tigecycline dosage based on age and clinical status of patient.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

tygacil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Positive cultures for rapidly growing mycobacteria
* Patients who have drug resistant isolates or are intolerant of macrolides or have serious infections unresponsive to currently available drugs
* Adults and children 10 years of age and older
* Pretreatment isolate of M. avium complex available for MIC determination
* Available for followup appointments